Novo Nordisk Stock Drops 56% Over Twelve Months as Investors Weigh Buy-the-Dip Opportunity

Summary

Forbes contributor Trefis Team published an analysis examining whether Novo Nordisk (NVO) stock, which has declined 56% over twelve months, represents a buying opportunity. The article focuses on the pharmaceutical company's GLP-1 drug portfolio and compares NVO with competitor Eli Lilly (LLY). This article is a standard equity investment analysis piece with no meaningful connection to artificial intelligence, AI engineering, or enterprise technology. While Novo Nordisk and Eli Lilly operate in